Replacing Both Ventricles with the Total Artificial Heart Eliminates Complications Including Right Heart Failure
Tucson, Ariz. (Vocus) May 12, 2009 -- According to INTERMACS data recently published in SynCardia’s 2008 Annual Report, the SynCardia temporary CardioWest™ Total Artificial Heart has a bridge-to-transplant rate of 72% at 6 months. This is double the bridge-to-transplant rate for Biventricular Assist Devices (BiVADS) at 36% and Left Ventricular Assist Devices (LVADs) at 27% (see Chart 1).
Unlike BiVADs and LVADs which assist the heart ventricle(s), the Total Artificial Heart replaces both dying heart ventricles. This eliminates complications caused by a dying heart including right native heart failure.
According to INTERMACS, 8% of BiVAD patients and 10% of LVAD patients experience right heart failure (see Chart 2). These patients often require treatment with inotropes and/or implantation of a right ventricular assist device. Total Artificial Heart patients are not subject to right native heart failure because the dying heart ventricles have been removed.
INTERMACS is the US national registry for patients with mechanical circulatory support devices that treat advanced heart failure. By applying uniform definitions and standards, INTERMACS levels the playing field for all mechanical circulatory support devices. INTERMACS tracks patient survival, adverse events and cause of death over time by patient profile, device and device category.
INTERMACS was created as a joint effort of the National Heart, Lung and Blood Institute (NHLBI), the Centers for Medicare and Medicaid Services (CMS), the Food and Drug Administration (FDA) and the United Network for Organ Sharing (UNOS) among others.
Originally designed as a permanent replacement heart, the Total Artificial Heart is currently approved as a bridge to human heart transplant for patients dying from end-stage biventricular failure. The Total Artificial Heart is the only device that provides immediate, safe blood flow of up to 9.5 L/min through both ventricles.
The SynCardia Total Artificial Heart is the first and only FDA, Health Canada and CE Mark approved Total Artificial Heart in the world. There have been more than 790 implants of the Total Artificial Heart, accounting for more than 160 patient years of life on the device.
Read the full story at http://www.prweb.com/releases/2009/05/prweb2404984.htm.
Copyright©2009 Vocus, Inc.
All rights reserved